Immediate and midterm outcomes following primary PCI with bioresorbable vascular scaffold implantation in patients with ST-segment myocardial infarction: Insights from the multicentre registro absorb italiano (RAI registry)

EuroIntervention

Volumn 11, Issue 2, 2015, Pages 157-162

  Ielasi, Alfonso ^a   Cortese, Bernardo ^b   Varricchio, Attilio ^c   Tespili, Maurizio ^a   Sesana, Marco ^d   Pisano, Francesco ^e   Loi, Bruno ^f   Granata, Francesco ^c   Moscarella, Elisabetta ^c   Orrego, Pedro Silva ^b   La Vecchia, Luigi ^g   Steffenino, Giuseppe ^h  

^a BOLOGNINI HOSPITAL   (Italy)

^b FATEBENEFRATELLI HOSPITAL   (Italy)

^c MONALDI HOSPITAL   (Italy)

^d Department of Cardiology   (Italy)

^e Ospedale Regionale U Parini   (Italy)

^f BROTZU HOSPITAL   (Italy)

^g SAN BORTOLO HOSPITAL   (Italy)

^h USD Emodinamica AO S Croce e Carle   (Italy)

Author keywords

Bioresorbable vascular scaffold; Outcome; Percutaneous coronary intervention; ST segment elevation myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PRASUGREL; TICAGRELOR; EVEROLIMUS;

ADULT; AGED; ARTICLE; BIORESORBABLE SCAFFOLD; BIORESORBABLE VASCULAR SCAFFOLD; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE REGISTRY; FEMALE; FOLLOW UP; HEART MUSCLE REVASCULARIZATION; HEART REINFARCTION; HUMAN; ITALY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDY; RETREATMENT; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; CLINICAL EFFECTIVENESS; DUAL ANTIPLATELET THERAPY; EQUIPMENT DESIGN; REPEAT PROCEDURE; TREATMENT OUTCOME; TREATMENT RESPONSE; ADOLESCENT; BIODEGRADABLE IMPLANT; CLINICAL TRIAL; DRUG ELUTING STENT; MIDDLE AGED; MYOCARDIAL INFARCTION; PROCEDURES; REGISTER; YOUNG ADULT;

ABSORBABLE IMPLANTS; ADOLESCENT; ADULT; AGED; COHORT STUDIES; DRUG-ELUTING STENTS; EVEROLIMUS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDIES; REGISTRIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84933529617     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJY14M10_11     Document Type: Article

References (28)

1. Canadian Cardiovascular Society; American Academy of Family Physicians; American College of Cardiology; American Heart Association, Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Halasyamani LK, Hochman JS, Krumholz HM, Lamas GA, Mullany CJ, Pearle DL, Sloan MA, Smith SC Jr, Anbe DT, Kushner FG, Ornato JP, Jacobs AK, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Halperin JL, Hunt SA, Lytle BW, Nishimura R, Page RL, Riegel B, Tarkington LG, Yancy CW. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2008;51:210-47.
2. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van 't Hof A, Widimsky P, Zahger D. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33:2569-619.
3. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Kirtane AJ, Parise H, Mehran R; HORIZONSAMI Trial Investigators. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008;358:2218-30.
4. Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH, Antman EM; TRITON-TIMI 38 investigators. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet. 2009;373:723-31.
5. Steg PG, James S, Harrington RA, Ardissino D, Becker RC, Cannon CP, Emanuelsson H, Finkelstein A, Husted S, Katus H, Kilhamn J, Olofsson S, Storey RF, Weaver WD, Wallentin L; PLATO Study Group. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation. 2010;122:2131-41.
6. De Luca G, Navarese EP, Suryapranata H. A meta-analytic overview of thrombectomy during primary angioplasty. Int J Cardiol. 2013;166:606-12.
7. Palmerini T, Biondi-Zoccai G, Della Riva D, Mariani A, Sabate M, Valgimigli M, Frati G, Kedhi E, Smits PC, Kaiser C, Genereux P, Galatius S, Kirtane AJ, Stone GW. Clinical outcomes with drug-eluting and bare-metal stents in patients with ST-segment elevation myocardial infarction: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol. 2013;62:496-504.
8. Bangalore S, Amoroso N, Fusaro M, Kumar S, Feit F. Outcomes with various drug-eluting or bare metal stents in patients with ST-segment-elevation myocardial infarction: a mixed treatment comparison analysis of trial level data from 34 068 patientyears of follow-up from randomized trials. Circ Cardiovasc Interv. 2013;6:378-90.
9. Serruys PW, Garcia-Garcia HM, Onuma Y. From metallic cages to transient bioresorbable scaffolds: change in paradigm of coronary revascularization in the upcoming decade? Eur Heart J. 2012;33:16-25b.
10. Ormiston JA, Serruys PW, Regar E, Dudek D, Thuesen L, Webster MW, Onuma Y, Garcia-Garcia HM, McGreevy R, Veldhof S. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet. 2008;371:899-907.
11. Serruys PW, Ormiston JA, Onuma Y, Regar E, Gonzalo N, Garcia-Garcia HM, Nieman K, Bruining N, Dorange C, Miquel-Hebert K, Veldhof S, Webster M, Thuesen L, Dudek D. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet. 2009;373:897-910.
12. Gomez-Lara J, Garcia-Garcia HM, Onuma Y, Garg S, Regar E, De Bruyne B, Windecker S, McClean D, Thuesen L, Dudek D, Koolen J, Whitbourn R, Smits PC, Chevalier B, Dorange C, Veldhof S, Morel MA, de Vries T, Ormiston JA, Serruys PW. A comparison of the conformability of everolimus-eluting bioresorbable vascular scaffolds to metal platform coronary stents. JACC Cardiovasc Interv. 2010;3:1190-8.
13. Diletti R, Farooq V, Girasis C, Bourantas C, Onuma Y, Heo JH, Gogas BD, van Geuns RJ, Regar E, de Bruyne B, Dudek D, Thuesen L, Chevalier B, McClean D, Windecker S, Whitbourn RJ, Smits P, Koolen J, Meredith I, Li X, Miquel-Hebert K, Veldhof S, Garcia-Garcia HM, Ormiston JA, Serruys PW. Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: does bioresorption matter with small vessel size? Insight from the ABSORB cohort B trial. Heart. 2013;99:98-105.
14. Kocka V, Maly M, Tousek P, Budesinsky T, Lisa L, Prodanov P, Jarkovsky J, Widimsky P. Bioresorbable vascular scaffolds in acute ST-segment elevation myocardial infarction: a prospective multicentre study 'Prague 19'. Eur Heart J. 2014;35:787-94.
15. Diletti R, Karanasos A, Muramatsu T, Nakatani S, Van Mieghem NM, Onuma Y, Nauta ST, Ishibashi Y, Lenzen MJ, Ligthart J, Schultz C, Regar E, de Jaegere PP, Serruys PW, Zijlstra F, van Geuns RJ. Everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with ST-segment elevation myocardial infarction: BVS STEMI first study. Eur Heart J. 2014;35:777-86.
16. Onuma Y, Serruys PW, Perkins LE, Okamura T, Gonzalo N, Garcia-Garcia HM, Regar E, Kamberi M, Powers JC, Rapoza R, van Beusekom H, van der Giessen W, Virmani R. Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human optical coherence tomography images in the ABSORB trial. Circulation. 2010;122:2288-300.
17. Onuma Y, Serruys PW. Bioresorbable scaffold: the advent of a new era in percutaneous coronary and peripheral revascularization? Circulation. 2011;123:779-97.
18. Gibson CM, de Lemos JA, Murphy SA, Marble SJ, McCabe CH, Cannon CP, Antman EM, Braunwald E; TIMI Study Group. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy. Circulation. 2001;103:2550-4.
19. Nakatani S, Onuma Y, Ishibashi Y, Muramatsu T, Iqbal J, Zhang YJ, van Geuns RJ, Ormiston JA, Serruys PW. Early (before 6 months), late (6-12 months) and very late (after 12 months) angiographic scaffold restenosis in the ABSORB Cohort B trial. EuroIntervention. 2015;10:1288-98.
20. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW; Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344-51.
21. Hong MK, Mintz GS, Lee CW, Kim YH, Lee SW, Song JM, Han KH, Kang DH, Song JK, Kim JJ, Park SW, Park SJ. Incidence, mechanism, predictors, and long-term prognosis of late stent malapposition after bare-metal stent implantation. Circulation. 2004;109:881-6.
22. Hong MK, Mintz GS, Lee CW, Park DW, Park KM, Lee BK, Kim YH, Song JM, Han KH, Kang DH, Cheong SS, Song JK, Kim JJ, Park SW, Park SJ. Late stent malapposition after drug-eluting stent implantation: an intravascular ultrasound analysis with long-term follow-up. Circulation. 2006;113:414-9.
23. Ormiston JA, Serruys PW, Onuma Y, van Geuns RJ, de Bruyne B, Dudek D, Thuesen L, Smits PC, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Hebert KM, Rapoza R, Garcia-Garcia HM. First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multiimaging modality study. Circ Cardiovasc Interv. 2012;5:620-32.
24. Kajiya T, Liang M, Sharma RK, Lee CH, Chan MY, Tay E, Chan KH, Tan HC, Low AF. Everolimus-eluting bioresorbable vascular scaffold (BVS) implantation in patients with ST-segment elevation myocardial infarction (STEMI). EuroIntervention. 2013;9:501-4.
25. Wiebe J, Mollmann H, Most A, Dorr O, Weipert K, Rixe J, Liebetrau C, Elsasser A, Achenbach S, Hamm C, Nef H. Short-term outcome of patients with ST-segment elevation myocardial infarction (STEMI) treated with an everolimus-eluting bioresorbable vascular scaffold. Clin Res Cardiol. 2014;103:141-8.
26. Gori T, Schulz E, Hink U, Wenzel P, Post F, Jabs A, Munzel T. Early outcome after implantation of Absorb bioresorbable drugeluting scaffolds in patients with acute coronary syndromes. EuroIntervention. 2013;9:1036-41.
27. Farooq V, Serruys PW, Heo JH, Gogas BD, Onuma Y, Perkins LE, Diletti R, Radu MD, Raber L, Bourantas CV, Zhang Y, van Remortel E, Pawar R, Rapoza RJ, Powers JC, van Beusekom HM, Garcia-Garcia HM, Virmani R. Intracoronary optical coherence tomography and histology of overlapping everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: the potential implications for clinical practice. JACC Cardiovasc Interv. 2013;6:523-32.
28. Farooq V, Onuma Y, Radu M, Okamura T, Gomez-Lara J, Brugaletta S, Gogas BD, van Geuns RJ, Regar E, Schultz C, Windecker S, Lefevre T, Brueren BR, Powers J, Perkins LL, Rapoza RJ, Virmani R, Garcia-Garcia HM, Serruys PW. Optical coherence tomography (OCT) of overlapping bioresorbable scaffolds: from benchwork to clinical application. EuroIntervention. 2011;7:386-99.